-
Haier Biomedical Terminates Acquisition Plan for Shanghai RAAS
•
Haier Biomedical (SHA: 688139) has announced the termination of its plan to acquire Shanghai RAAS (SHE: 002252), along with the associated share issuance for fundraising. The company cited the complex deal structure and the lack of a specific plan recognized by all parties involved as the reason for the termination,…
-
Grifols Completes Sale of 20% Stake in Shanghai RAAS to Haier Group for RMB 12.5 Billion
•
Grifols AS (NASDAQ: GRFS), a Spain-based global leader in the production of blood products, has announced the completion of a significant transaction where it sold a 20% stake in Shanghai RAAS Blood Products Co., Ltd (SHE: 002252) to Haier Group, a Chinese electronics and appliances conglomerate, for RMB 12.5 billion…
-
Shanghai RAAS Receives NMPA Approval to Initiate Clinical Trial for Hemophilia Preventive Treatment
•
Shanghai RAAS (SHE: 002252), a biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to commence a Phase I clinical study for SR604. The drug candidate is intended as a preventive treatment for bleeding episodes in patients with hemophilia and…
-
Grifols AS Plans to Sell Stake in Shanghai RAAS Blood Products Co., Ltd for Up to $1.5 Billion
•
Spain-based Grifols AS (NASDAQ: GRFS), a leading global player in the blood products industry, has announced its intention to sell a portion of its stake in China-based Shanghai RAAS Blood Products Co., Ltd (SHE: 002252). This strategic move is expected to yield up to USD 1.5 billion for Grifols AS,…
